佐力药业(300181) - 2025年10月30日投资者关系活动记录表

Group 1: Company Performance and Sales - As of the end of Q3 2025, Wuling Capsules have been adopted by over 15,000 hospitals, with ongoing collection procurement in 6 provinces including Zhejiang and Shanghai [2] - The company expects Wuling Capsules to maintain steady growth, driven by market access benefits from national procurement and enhanced patient education [2] - The Bai Ling series has been included in national procurement across 30 provinces, with a goal to achieve a sales scale of 1 billion RMB for Bai Ling Tablets [3] Group 2: Marketing and Distribution Strategies - The company is actively expanding its presence in chain pharmacies and has formed strategic partnerships with leading pharmacy chains to enhance patient management [4] - Digital marketing efforts are being intensified through collaborations with platforms like Meituan and Ele.me, aiming to capture the young user market [4] - The company plans to integrate other products into its retail strategy to enhance overall product distribution and sales [4] Group 3: Impact of Procurement Policies - The upcoming national procurement 2.0 for traditional Chinese medicine (TCM) is expected to include nearly 100 products, which may lead to price reductions but also promote industry standardization [5][6] - The company is enhancing its competitive edge by collaborating with standardized planting bases and establishing a traceability system for TCM products [6] Group 4: Financial Metrics and Projections - The overall gross margin has slightly decreased due to changes in product mix and price reductions from procurement policies affecting Wuling and Bai Ling series products [9] - Accounts receivable have increased due to higher sales revenue and longer payment cycles from hospital clients, aligning with the company's credit policies [9]